Rx Name [DABIGATRAN, 20120412]
|
|
PRADAX 110MG TAB (BOE/STO) DABIGATRAN
|
|
|
|
|
|
20120412
|
|
|
DIRECT THROMBIN INHIBITORS
|
|
|
Dabigatran is a direct thrombin inhibitor. It is used for the prophylaxis of venous thromboembolism in patients undergoing orthopaedic surgery and the prevention of stroke and systemic embolisation in patients with non-vavular atrial fibrillation. Can be
|
|
|
Dabigatran should not be used in patients who are at a high risk for bleeding. It is contraindicated for those patients who have mechanical prosthetic heart valves because of thromboembolism and major bleeding. Dabigatran should be used with caution in patients with hepatic impairment and the dose should be reduced or avoided in patients with renal impairment.The most common side effect is bleeding. Dyspepsia, gastritis, nausea, and diarrhoea are also common. If bleeding occurs, stop treatment and initiate surgical haemostasis or blood volume replacement.
|
|
|
Prophylaxis of venous embolism after orthropaedic surgery: Adult: 18-74 years, 110mg to be taken 1-4 hours after surgery, followed by 220mg once daily for 9 days , to be taken 12-24 hours after initial dose. Adult: 75years and older 110mg to be taken afte
|
|
|
|
|
|
|
|
|
|
|
|
|